Ischemic stroke
The most common kind of stroke. A blood clot blocks or plugs a blood vessel in the brain, so part of the brain stops getting the blood it needs. Brain cells start to die within a few minutes without that supply. Two US government patient pages give different shares for how common it is: about 80% of strokes on one page and just under 90% on the other.
- Condition
- In this atlas
Overview
Technical summary
MeSH descriptor D000083242 (Ischemic Stroke). Its scope note covers stroke from reduced blood flow to part of the brain, with a thrombotic form (a clot that forms in a brain vessel) and an embolic form (an obstruction that forms elsewhere and moves to the brain). Sits beside the pages for bleeding in the brain, subarachnoid hemorrhage and transient ischemic attack under the general stroke record. The text rests on the MeSH scope note and two US government patient pages; no trial or guideline evidence is recorded on this page.
Recognition
A US government patient page says the symptoms of a stroke often happen quickly. They include sudden numbness or weakness of the face, arm or leg, often affecting only one side of the body; sudden confusion, or sudden trouble speaking or following speech; and sudden trouble seeing in one or both eyes.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Tenecteplase
Applies to Adult Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction
Population, setting and follow-up
- Adult patients described in the indications sections of the label.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passages read state
The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 638
Record details
- Record id
cardio:ischemic-stroke- Content hash
88474a95c448b1a3211b6e092faa364be4cfef9e527bcbc7f25c166a7215e061